For its third fiscal quarter (ending September 30), Cytokinetics Inc (NASDAQ: CYTK) has reported E.P.S. of $-1.35 compared to $-1.52 a year ago. This result fell short of the consensus estimate of $-0.78 by $-0.57. For the latest four quarters through September 30, E.P.S. were $-5.52 compared to $-3.21 a year ago.
Recent Price Action
Cytokinetics Inc (NASDAQ: CYTK) stock closed at $34.64 on 11/2/23 after a decline of -1.3%. Relative to the market the stock has been weak over the last nine months but has risen 6.3% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to fall short of the cost of capital, CYTK is expected to be a major Value Eraser.
Cytokinetics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment